CU20160073A7 - 2,6 purinas di-sustituidas útiles en el tratamiento de trastornos proliferativos tales como el cáncer - Google Patents
2,6 purinas di-sustituidas útiles en el tratamiento de trastornos proliferativos tales como el cáncerInfo
- Publication number
- CU20160073A7 CU20160073A7 CUP2016000073A CU20160073A CU20160073A7 CU 20160073 A7 CU20160073 A7 CU 20160073A7 CU P2016000073 A CUP2016000073 A CU P2016000073A CU 20160073 A CU20160073 A CU 20160073A CU 20160073 A7 CU20160073 A7 CU 20160073A7
- Authority
- CU
- Cuba
- Prior art keywords
- cancer
- treatment
- proliferative disorders
- compounds
- used substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a compuestos de Ia Fórmula (I) ESPACIO PARA FÓRMULA o sales de aquellos aceptables desde el punto de vista farmacéutico, en donde Q, G, anillo A, anillo B, R¹, R2 , R3 , R4, R5 , R5a , R6, R7 , R8 , R9 , R 10 , R11 , R12 , R13 , R14 , R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 y m son como se definen en Ia presente. Los derivados de purina novedosos son útiles para tratar el crecimiento celular anormal, tal como el cáncer, en mamíferos. Otras formas de realización se refieren a composiciones farmacéuticas que contienen los compuestos y a métodos para usar los compuestos y las composiciones en el tratamiento del crecimiento celular anormal en mamíferos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907322P | 2013-11-21 | 2013-11-21 | |
| PCT/IB2014/065935 WO2015075598A1 (en) | 2013-11-21 | 2014-11-10 | 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20160073A7 true CU20160073A7 (es) | 2016-10-28 |
| CU24402B1 CU24402B1 (es) | 2019-05-03 |
Family
ID=52004011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2016000073A CU24402B1 (es) | 2013-11-21 | 2014-11-10 | 2,6 purinas di-sustituidas útiles en el tratamiento de trastornos proliferativos tales como cáncer |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US9290496B2 (es) |
| EP (1) | EP3071570B1 (es) |
| JP (2) | JP6166845B2 (es) |
| KR (1) | KR101919672B1 (es) |
| CN (1) | CN105916853B (es) |
| AP (1) | AP2016009219A0 (es) |
| AR (1) | AR098492A1 (es) |
| AU (1) | AU2014351433B2 (es) |
| CA (1) | CA2931034C (es) |
| CL (1) | CL2016001151A1 (es) |
| CR (1) | CR20160236A (es) |
| CU (1) | CU24402B1 (es) |
| CY (1) | CY1120478T1 (es) |
| DK (1) | DK3071570T3 (es) |
| DO (1) | DOP2016000115A (es) |
| EA (1) | EA029842B1 (es) |
| ES (1) | ES2681799T3 (es) |
| GE (2) | GEP20186878B (es) |
| GT (1) | GT201600091A (es) |
| HR (1) | HRP20181036T1 (es) |
| HU (1) | HUE039858T2 (es) |
| IL (1) | IL245698B (es) |
| LT (1) | LT3071570T (es) |
| MA (1) | MA39043B1 (es) |
| MD (1) | MD20160053A2 (es) |
| MX (1) | MX2016006397A (es) |
| MY (1) | MY184433A (es) |
| NI (1) | NI201600072A (es) |
| PE (1) | PE20160885A1 (es) |
| PH (1) | PH12016500911A1 (es) |
| PL (1) | PL3071570T3 (es) |
| PT (1) | PT3071570T (es) |
| RS (1) | RS57537B1 (es) |
| SI (1) | SI3071570T1 (es) |
| TN (1) | TN2016000188A1 (es) |
| TW (1) | TWI538913B (es) |
| UA (1) | UA115388C2 (es) |
| UY (1) | UY35845A (es) |
| WO (1) | WO2015075598A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| RU2650512C2 (ru) * | 2013-09-18 | 2018-04-16 | Бейджин Ханми Фармасьютикал Ко., Лтд. | Соединение, ингибирующее активности киназ ВТК и/или JAK3 |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US20180201614A1 (en) * | 2015-05-12 | 2018-07-19 | Kalyra Pharmaceuticals, Inc. | Bicyclic compounds |
| EP4086257A1 (en) * | 2016-09-30 | 2022-11-09 | SRI International | Dual clk/cdk1 inhibitors for cancer treatment |
| EP3541389A1 (en) | 2016-11-16 | 2019-09-25 | Pfizer Inc | Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer |
| CN110753693A (zh) | 2016-12-23 | 2020-02-04 | 阿尔维纳斯运营股份有限公司 | Egfr蛋白水解靶向嵌合分子和相关使用方法 |
| ES2910083T3 (es) | 2017-03-10 | 2022-05-11 | Pfizer | Derivados de imidazo[4,5-c]quinolina cíclicos sustituidos |
| SG10202110112TA (en) | 2017-03-10 | 2021-10-28 | Pfizer | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors |
| EP3814354B1 (en) * | 2018-06-22 | 2023-11-08 | The Royal Institution for the Advancement of Learning / McGill University | Purine compounds and method for the treatment of cancer |
| WO2020175968A1 (ko) * | 2019-02-28 | 2020-09-03 | 주식회사 보로노이 | N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 약학적 조성물 |
| WO2020181050A1 (en) | 2019-03-05 | 2020-09-10 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| CA3179612A1 (en) * | 2020-05-20 | 2021-11-25 | Tyk Medicines, Inc. | Compound used as ret kinase inhibitor and application thereof |
| WO2023041432A1 (en) | 2021-09-14 | 2023-03-23 | Boehringer Ingelheim International Gmbh | 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament |
| WO2026130278A1 (en) * | 2024-12-20 | 2026-06-25 | K2 Medicines (Nanjing) Co., Ltd. | Egfr tyrosine kinase inhibitor and use thereof |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| DE69222637T2 (de) | 1991-05-10 | 1998-02-26 | Rhone Poulenc Rorer Int | Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DK0780386T3 (da) | 1995-12-20 | 2003-02-03 | Hoffmann La Roche | Matrixmetalloproteaseinhibitorer |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| US6391874B1 (en) | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| AR007855A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen |
| EP0923585B1 (en) | 1996-07-18 | 2002-05-08 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
| US6790958B2 (en) | 1996-08-02 | 2004-09-14 | Robert T. Lum | Purine inhibitors of cyclin dependent kinase 2 & IKBA |
| US5866702A (en) | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
| US6794390B2 (en) | 1996-08-02 | 2004-09-21 | Cv Therapeutics, Inc. | Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha |
| EP0922030A1 (en) | 1996-08-23 | 1999-06-16 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| US6077864A (en) | 1997-01-06 | 2000-06-20 | Pfizer Inc. | Cyclic sulfone derivatives |
| HUP0000852A2 (hu) | 1997-02-03 | 2001-05-28 | Pfizer Products Inc. | Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények |
| JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | N−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
| NZ336836A (en) | 1997-02-11 | 2001-02-23 | Pfizer | Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments |
| CA2289102A1 (en) | 1997-05-07 | 1998-11-12 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| CA2291709A1 (en) | 1997-05-30 | 1998-12-03 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| WO1999007705A1 (en) | 1997-08-07 | 1999-02-18 | The Regents Of The University Of California | Purine inhibitor of protein kinases, g proteins and polymerases |
| DE69838172T2 (de) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
| AU744939B2 (en) | 1997-09-26 | 2002-03-07 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| SK6652000A3 (en) | 1997-11-11 | 2002-05-09 | Pfizer Prod Inc | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| KR100743287B1 (ko) | 1998-05-29 | 2007-07-26 | 수젠, 인크. | 피롤기로 치환된 2-인돌리논 단백질 인산화 효소 억제제 |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| CN1437594A (zh) | 2000-06-22 | 2003-08-20 | 辉瑞产品公司 | 用于治疗异常细胞生长的取代的双环衍生物 |
| AU2001290912A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| AR042586A1 (es) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| WO2002072549A1 (en) | 2001-03-12 | 2002-09-19 | Millennium Pharmaceuticals, Inc. | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
| US20040235867A1 (en) | 2001-07-24 | 2004-11-25 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
| US20060009642A1 (en) | 2001-10-12 | 2006-01-12 | Irm Llc, A Delaware Limited Liability Company | Methods for the synthesis of substituted purines |
| US6949644B2 (en) | 2001-10-12 | 2005-09-27 | Irm Llc | Methods for the synthesis of substituted purines |
| CA2463563A1 (en) | 2001-10-12 | 2003-04-17 | Irm Llc | Kinase inhibitor scaffolds and methods for their preparation |
| EP1556053A4 (en) | 2002-10-31 | 2006-04-19 | Amgen Inc | ANTI-INFLAMMATORY AGENTS |
| WO2005016268A2 (en) | 2003-08-08 | 2005-02-24 | Mitochroma Research, Inc. | Alimentary compositions and methods for metabolic modulation |
| WO2005020892A2 (en) | 2003-08-08 | 2005-03-10 | Mitochroma Research, Inc. | Pharmaceutical compositions and methods for metabolic modulation |
| JP2007502776A (ja) | 2003-08-15 | 2007-02-15 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Rtk阻害剤としての6−置換アニリノプリン類 |
| US20060029642A1 (en) | 2004-08-03 | 2006-02-09 | Dusan Miljkovic | Methods and compositions for improved chromium complexes |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| FR2876583B1 (fr) | 2004-10-15 | 2007-04-13 | Centre Nat Rech Scient Cnrse | Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
| GB0502573D0 (en) | 2005-02-08 | 2005-03-16 | Topotarget As | Therapeutic compounds |
| GB0526246D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| US20070253896A1 (en) | 2006-02-07 | 2007-11-01 | Conforma Therapeutics Corporation | 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors |
| EP2008210A1 (en) | 2006-03-15 | 2008-12-31 | Csir | Modulation of phosphoryl transferase activity of glutamine synthetase |
| PT2076268E (pt) | 2006-10-19 | 2013-03-07 | Genzyme Corp | Roscovitina para o tratamento de certas doenças císticas |
| WO2008057402A2 (en) | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
| CA2676138A1 (en) | 2007-01-26 | 2008-08-07 | Irm Llc | Compounds and compositions as kinase inhibitors |
| EP2134723B1 (en) * | 2007-03-07 | 2017-07-12 | Boehringer Ingelheim International GmbH | 2,6 diamino-9h-purine derivatives and their use in the treatment of proliferative diseases |
| CN101842098A (zh) | 2007-08-10 | 2010-09-22 | 基因实验室技术有限公司 | 用于治疗病毒感染的含氮的二环化学实体 |
| KR20100068286A (ko) | 2007-10-17 | 2010-06-22 | 노파르티스 아게 | 아데노신 a1 수용체 리간드로서의 퓨린 유도체 |
| US9089572B2 (en) | 2008-01-17 | 2015-07-28 | California Institute Of Technology | Inhibitors of p97 |
| WO2010019392A1 (en) | 2008-08-13 | 2010-02-18 | Merck Sharp & Dohme Corp. | Purine derivatives for treatment of alzheimer's disease |
| AR073397A1 (es) * | 2008-09-23 | 2010-11-03 | Palau Pharma Sa | Derivados de (r) -3- (n,n-dimetilamino) pirrolidina |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| US8426428B2 (en) * | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
| WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
| KR101705158B1 (ko) * | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Egfr 억제제 및 질환 치료방법 |
| FR2945747A1 (fr) * | 2009-05-25 | 2010-11-26 | Centre Nat Rech Scient | Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| WO2011156889A1 (en) | 2010-06-14 | 2011-12-22 | Trt Pharma Inc. | Novel modulators of nrf2 and uses thereof |
| US20130172340A1 (en) | 2010-06-22 | 2013-07-04 | University of Central Flordia Research Foundation, | Substituted 2-(9h-purin-9-yl) acetic acid analogues as inhibitors of stat3 |
| KR20130139999A (ko) * | 2010-10-14 | 2013-12-23 | 어리어드 파마슈티칼스, 인코포레이티드 | Egfr-유도된 암의 세포 증식을 억제하는 방법 |
| JP5956999B2 (ja) * | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | ヘテロアリール化合物およびその使用 |
| EP2637502B1 (en) * | 2010-11-10 | 2018-01-10 | Celgene CAR LLC | Mutant-selective egfr inhibitors and uses thereof |
| AU2012250517B2 (en) * | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| US8762299B1 (en) | 2011-06-27 | 2014-06-24 | Google Inc. | Customized predictive analytical model training |
| MD20140023A2 (ro) | 2011-09-22 | 2014-06-30 | Pfizer Inc. | Derivaţi de pirolpirimidină şi purină |
| CN103159742B (zh) | 2011-12-16 | 2015-08-12 | 北京韩美药品有限公司 | 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用 |
| CA2861010A1 (en) | 2012-01-13 | 2013-07-18 | Xiao Xu | Heterocyclic compounds and uses as anticancer agents |
| CA2904797A1 (en) | 2013-03-14 | 2014-09-18 | Pfizer Inc. | Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer |
| US10884952B2 (en) | 2016-09-30 | 2021-01-05 | Intel Corporation | Enforcing memory operand types using protection keys |
-
2014
- 2014-10-11 UA UAA201605505A patent/UA115388C2/uk unknown
- 2014-11-10 KR KR1020167016053A patent/KR101919672B1/ko not_active Expired - Fee Related
- 2014-11-10 HR HRP20181036TT patent/HRP20181036T1/hr unknown
- 2014-11-10 MA MA39043A patent/MA39043B1/fr unknown
- 2014-11-10 MX MX2016006397A patent/MX2016006397A/es unknown
- 2014-11-10 MY MYPI2016701796A patent/MY184433A/en unknown
- 2014-11-10 JP JP2016532623A patent/JP6166845B2/ja not_active Expired - Fee Related
- 2014-11-10 GE GEAP201414151A patent/GEP20186878B/en unknown
- 2014-11-10 EA EA201600337A patent/EA029842B1/ru not_active IP Right Cessation
- 2014-11-10 CN CN201480073530.7A patent/CN105916853B/zh not_active Expired - Fee Related
- 2014-11-10 LT LTEP14806447.0T patent/LT3071570T/lt unknown
- 2014-11-10 RS RS20180909A patent/RS57537B1/sr unknown
- 2014-11-10 GE GEAP201814151A patent/GEAP201814151A/en unknown
- 2014-11-10 CU CU2016000073A patent/CU24402B1/es unknown
- 2014-11-10 EP EP14806447.0A patent/EP3071570B1/en active Active
- 2014-11-10 WO PCT/IB2014/065935 patent/WO2015075598A1/en not_active Ceased
- 2014-11-10 PT PT148064470T patent/PT3071570T/pt unknown
- 2014-11-10 AU AU2014351433A patent/AU2014351433B2/en not_active Ceased
- 2014-11-10 HU HUE14806447A patent/HUE039858T2/hu unknown
- 2014-11-10 DK DK14806447.0T patent/DK3071570T3/en active
- 2014-11-10 CA CA2931034A patent/CA2931034C/en active Active
- 2014-11-10 PL PL14806447T patent/PL3071570T3/pl unknown
- 2014-11-10 TN TN2016000188A patent/TN2016000188A1/fr unknown
- 2014-11-10 SI SI201430806T patent/SI3071570T1/sl unknown
- 2014-11-10 MD MDA20160053A patent/MD20160053A2/ro not_active Application Discontinuation
- 2014-11-10 PE PE2016000650A patent/PE20160885A1/es unknown
- 2014-11-10 ES ES14806447.0T patent/ES2681799T3/es active Active
- 2014-11-10 AP AP2016009219A patent/AP2016009219A0/en unknown
- 2014-11-19 UY UY0001035845A patent/UY35845A/es not_active Application Discontinuation
- 2014-11-20 AR ARP140104368A patent/AR098492A1/es unknown
- 2014-11-20 TW TW103140297A patent/TWI538913B/zh not_active IP Right Cessation
- 2014-11-20 US US14/548,749 patent/US9290496B2/en active Active
-
2016
- 2016-05-13 CL CL2016001151A patent/CL2016001151A1/es unknown
- 2016-05-17 PH PH12016500911A patent/PH12016500911A1/en unknown
- 2016-05-18 IL IL24569816A patent/IL245698B/en active IP Right Grant
- 2016-05-19 DO DO2016000115A patent/DOP2016000115A/es unknown
- 2016-05-20 NI NI201600072A patent/NI201600072A/es unknown
- 2016-05-20 CR CR20160236A patent/CR20160236A/es unknown
- 2016-05-20 GT GT201600091A patent/GT201600091A/es unknown
-
2017
- 2017-06-23 JP JP2017122759A patent/JP2017214390A/ja active Pending
-
2018
- 2018-07-25 CY CY20181100779T patent/CY1120478T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20160236A (es) | Derivados de purina 2,6- sustituidos y su uso en el tratamiento de desordenes proliferativos | |
| NI201400023A (es) | Derivados de pirrolopirimidina y purina | |
| MX2022012313A (es) | Oxisteroles y metodos de uso de los mismos. | |
| UY35641A (es) | PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO) | |
| CL2019000368A1 (es) | Inhibidores de cdk2/4/6. | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| SV2018005655A (es) | "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer" | |
| CL2019000512A1 (es) | Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica. | |
| MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
| MX2016007258A (es) | Profarmacos de amidas de piridona utiles como moduladores de canales de sodio. | |
| ECSP15012804A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| PE20160689A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas | |
| CR20150378A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| CU20170007A7 (es) | Compuestos de imidazopiridazina | |
| UY36228A (es) | Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen | |
| PY1515461A (es) | Derivados de Dihidropirrolopirimidina | |
| SV2016005310A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
| UY36023A (es) | “derivados cristalinos de (s)-1-((2r,3r,4s,5s)-5-alil-3-metoxi-4-(tosilmetil) tetrahidrofuran-2-il)-3-aminopropan-2-ol “. | |
| CU20140033A7 (es) | Derivados de pirrolopirimidina y purina | |
| TH160101A (th) | อนุพันธ์พิวรีนที่ถูกแทนที่ 2,6 และการใช้ของสิ่งเหล่านี้ในการรักษาของความผิดปกติ ที่มีการเพิ่มจำนวนมากกว่าปกติ | |
| ECSP14013253A (es) | Derivados de pirrolopirimidina y purina | |
| ECSP17003149A (es) | Compuestos de dihidroisoquinolinona sustituida |